Used in the treatment of moderate to severe atopic dermatitis, this antibody targets the IL-13 receptor alpha 1 subunit to block signaling of interleukin-13, a key cytokine involved in type 2 inflammation. By inhibiting this pathway, it helps reduce skin inflammation, itching, and barrier dysfunction commonly seen in chronic inflammatory skin diseases. It has been investigated for its efficacy in patients who do not respond adequately to topical therapies or other systemic treatments. Its high specificity allows for targeted therapy with potentially fewer systemic side effects compared to broad immunosuppressants.